drug

PP1M 100 mg eq.

as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Janssen, L.P. - Investigator Initiated Studies Program
1 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Investigational (via trials)
SchizophreniaSchizophrenia

Trials

1
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia
NCT01515423Phase 3Completed

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
Janssen, L.P. - Investigator Initiated Studies Program
company
trial
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia
PHASE3
trial
indication
Schizophrenia
indication
Schizophrenia
indication